Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream' - 2Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips
- 3Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- 4Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- 5Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- Intriguing Social Unesco World Legacy Locales All over The Planet
- What's going around right now? COVID, flu, stomach bug on the rise
- Moscow accuses Berlin of stifling the opposition
- New York to require social media platforms to display mental health warnings
- The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
- Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
